Tripoli - Manufacturing Plant

Advanced Manufacturing Facility Driving Innovation and Efficiency

The plant commenced operations in 2026 and represents a high-technology manufacturing facility producing solid oral dosage forms (tablets and capsules), primarily serving the fields of oncology, immunology, and central nervous system disorders.

More than 200 people are employed at the facility, fifty of whom work exclusively in the Research and Development Department.

The plant incorporates energy-saving installations, while extensive use of robotics and artificial intelligence is implemented, mainly to automate processes and enhance the production efficiency of its units.